Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly, the maker of the popular injectable Mounjaro, has just released the surprising phase 3 trial results for its new ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Results involving the highest dose of orforglipron disappointed investors — but still bring the drug a step closer to ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

Pharmaceutical giant Eli Lilly said last week that it will raise the U.K. list price of its weight-loss treatment Mounjaro by ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...